Harrow (NASDAQ:HROW) Cut to “Strong Sell” at Zacks Research

Zacks Research downgraded shares of Harrow (NASDAQ:HROW) from a hold rating to a strong sell rating in a report released on Tuesday morning,Zacks.com reports.

A number of other research analysts also recently commented on HROW. LADENBURG THALM/SH SH boosted their price target on Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Cantor Fitzgerald reduced their price target on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a research report on Wednesday. HC Wainwright upped their target price on Harrow from $69.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, William Blair reiterated an “outperform” rating on shares of Harrow in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $71.14.

Harrow Stock Performance

Shares of NASDAQ:HROW opened at $36.17 on Tuesday. Harrow has a 12-month low of $20.85 and a 12-month high of $54.85. The company’s 50 day moving average price is $47.92 and its two-hundred day moving average price is $43.71. The firm has a market cap of $1.35 billion, a PE ratio of -212.75 and a beta of 0.05. The company has a quick ratio of 2.52, a current ratio of 2.20 and a debt-to-equity ratio of 4.67.

Harrow (NASDAQ:HROW) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.23). The company had revenue of $89.09 million during the quarter, compared to the consensus estimate of $88.42 million. Harrow had a negative net margin of 1.89% and a positive return on equity of 36.51%. Equities research analysts predict that Harrow will post -0.53 earnings per share for the current year.

Institutional Investors Weigh In On Harrow

Several hedge funds have recently modified their holdings of HROW. University of Texas Texas AM Investment Management Co. bought a new position in Harrow in the fourth quarter valued at about $26,000. Raymond James Financial Inc. acquired a new position in shares of Harrow in the second quarter valued at approximately $48,000. SBI Securities Co. Ltd. raised its holdings in Harrow by 393.5% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after buying an additional 846 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in Harrow during the 3rd quarter worth approximately $83,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Harrow by 25.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after buying an additional 369 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Key Headlines Impacting Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and raised its price target to $70, signaling continued upside from that shop despite recent volatility. H.C. Wainwright PT Raised
• Positive Sentiment: Company reported record 2025 results and set a 2026 outlook, underscoring underlying revenue momentum that management says supports growth investments. Record 2025 Results
• Positive Sentiment: Management outlined a $350M–$365M 2026 revenue goal tied to salesforce expansion and pipeline progress — a constructive guide for top-line growth if execution holds. 2026 Revenue Goal
• Neutral Sentiment: Cantor Fitzgerald trimmed its price target slightly (from $94 to $91) but remains Overweight, leaving a large implied upside from current levels — mixed signal on conviction. Cantor Fitzgerald PT Change
• Neutral Sentiment: Management will present at the Leerink Global Healthcare Conference (Mar 10), giving investors another opportunity for management commentary and Q&A. Leerink Presentation
• Negative Sentiment: Zacks Research downgraded Harrow from Hold to Strong Sell, increasing bearish analyst pressure and likely contributing to near-term selling. Zacks Downgrade Coverage
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS forecasts (Q3: $0.29 → $0.20; Q4: $0.51 → $0.40), reflecting weaker near-term profit expectations even while the firm keeps a Buy rating. HC Wainwright Estimate Cuts
• Negative Sentiment: Investors reacted to a disappointing Q4 EPS print (reported EPS well below consensus), margin pressure, and warnings about higher S&M and interest expense; analysts and outlets highlighted valuation and leverage concerns. Coverage and analyses explain the post-earnings selloff. Earnings Transcript SA Analysis Shares Gap Down

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.